Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Scientific reports · 2023
    SHSandra Huicochea CastellanosJIJana IvanidzeJTJones T. NauseefSTScott T. TagawaJRJoseph Reginald Osborne
    PMID: 37221397PMCID: PMC10205741DOISenior author15 citations
  2. 2
    European journal of nuclear medicine and molecular imaging · 2025
    JRJoseph Reginald Osborne
    PMID: 40325261PMCID: PMC12491383DOISenior author3 citations
  3. 3
    Translational oncology · 2022
    SHSandra Huicochea CastellanosSTScott T. TagawaJRJoseph Reginald Osborne
    PMID: 36571987PMCID: PMC9803810DOISenior author6 citations

Publications

153 publications

Funding

17 grantsView NIH portfolio on RePORTER ↗

Active

8 grants
  • Co-I
    ESCAPE - Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate Cancer
    National Cancer Institute · 2024–2029
    R37CA282407-01A1
  • Co-I
    Whole-Body MRI Assessment of Body Composition Remodeling During GLP-1 Agonist Therapy for Obesity
    Radiological Society of North America · 2026–2028
    RSNA 260380-01
  • Co-I
    Optimization of Prostate-Specific Membrane Antigen-Targeted Radiation
    Prostate Cancer Foundation · 2017–2027
    17CHAL11
  • KP
    Modernization and Expansion of the Citigroup Biomedical Imaging Center at Weill Cornell Medical College
    Office of the Director, NIH · 2023–2027
    C06OD036045-01
  • Co-I
    Development and optimization of CEACAM5-targeted alpha emitters
    Prostate Cancer Foundation · 2025–2027
    24CHAL11
  • Co-I
    Heating cold prostate tumors with PSMA-targeted alpha therapy and pembrolizumab
    U.S. Department of Defense · 2020–2026
    W81XWH-20-1-0706
  • Co-I
    Comprehensive Assessment of Cancer Theranostics Response
    National Cancer Institute · 2023–2026 · via AIQ Global, Inc.
    R44CA285006-01
  • KP
    New PET/CT System for Human and Non-human Primate Imaging
    Office of the Director, NIH · 2023–2026
    S10OD034271-01
Completed grants (9)
  • Co-I
    MRI Detection of CarotId Plaques as a mecHanism for Embolic strokes of undeteRmined source (MRI DECIPHER)
    National Heart, Lung, and Blood Institute · 2019–2025
    R01HL144541-05
  • KP
    Evaluation of prostate specific membrane antigen (PSMA) as a radiotherapeutic target in glioblastoma multiforme (GBM)
    Radiological Society of North America · 2024–2024
    RSNA 230525-01
  • Co-I
    Understanding the dynamic interactions between tau pathology and microgliamediated inflammation in Alzheimer's Disease
    National Institute on Aging · 2021–2024
    R01AG072753-01A1
  • KP
    Major Cyclotron Upgrades and Refurbishment
    Office of the Director, NIH · 2021–2023
    S10OD030447-01
  • MPI
    124I-NaI PET: Building block for precision medicine in metastatic thyroid cancer
    National Cancer Institute · 2019–2021 · via Memorial Sloan Kettering Cancer Center
    R01CA201250-05
  • PI
    A new technique to make 68Ga-labeled pharmaceuticals widely available for clinical use
    National Cancer Institute · 2018–2021
    R01CA207645-03
  • KP
    Imaging Neuroinflammation in Alzheimer's Disease (AD) with [11C] Arachidonic Acid and PET
    National Institute on Aging · 2009–2013
    RC2AG036502-02EWO
  • PI
    ImmunoPET Based on Anti-PSMA Antibody, 89Zr-J591 for Molecular Imaging of Prostate Cancer
    National Cancer Institute · 2011–2012
    R21CA153177-01A1
  • KP
    Questionable Dementia II: Course and Predictors of Outcome
    National Institute on Aging · 2010–2011
    R01AG017761-14EWO

Clinical research

7 studies

Active

2 studies
  • PI
    Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
    PHASE1 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
    Prostate Cancer
    NCT04886986
  • PI
    WCM catchment Prostate Cancer Health Impact Program (pCHIP) 2
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
Completed & closed trials (5)
  • PI
    A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Combined With Magnetic Resonance Imaging (MRI) Compared to Standard of Care (SOC) for the Detection of Prostate Cancer (PCa).
    PHASE3 · Telix Pharmaceuticals (Innovations) Pty Ltd. · CLOSED TO ACCRUAL (as of 2026)
    PCA; Prostate Cancer; Prostatic Neoplasm; PSMA PET; Diagnostic Imaging; Elevated PSA; Positron Emission Tomography; Prostate Biopsy; Carcinoma of the Prostate
    NCT07052214
  • PI
    Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
    PHASE1 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
    Prostate Cancer
    NCT04506567
  • PI
    An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer
    PHASE1; PHASE2 · Blue Earth Therapeutics Limited · CLOSED TO ACCRUAL (as of 2025)
    Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; mCRPC; Urogenital Neoplasms; Prostatic Neoplasms; Prostatic Diseases
    NCT05413850
  • PI
    WCM Catchment Prostate Cancer Health Impact Program (pCHIP)
    Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)
    Prostate Cancer
    NCT04293406
  • PI
    Evaluation of a 68Ga Small Molecule PSMA Antagonist Produced by Two Different Methods
    PHASE1; PHASE2 · Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)
    Metastatic Prostate Adenocarcinoma
    NCT04685811

Mentoring

4 menteesAll publications with mentees →

External relationships

Advisory/Scientific Board Member

Telix Pharmaceuticals (Innovations) Pty Ltd.

Other

Siemens Medical Solutions USA INC · Telix Pharmaceuticals (Innovations) Pty Ltd.